Combined impact of plasma phospho-tau 217, GFAP and NfL on longitudinal domain-specific cognitive decline

Abstract

Clinical trials are increasingly focused on pre-manifest and early Alzheimer’s disease. Accurately predicting clinical progression is important to avoid unnecessary treatment and improve trial efficiency.

The paper